NO984106L - Azolobenzazepin-derivater som neurologisk aktive midler - Google Patents

Azolobenzazepin-derivater som neurologisk aktive midler

Info

Publication number
NO984106L
NO984106L NO984106A NO984106A NO984106L NO 984106 L NO984106 L NO 984106L NO 984106 A NO984106 A NO 984106A NO 984106 A NO984106 A NO 984106A NO 984106 L NO984106 L NO 984106L
Authority
NO
Norway
Prior art keywords
azolobenzazepine
derivatives
active agents
neurologically active
neurologically
Prior art date
Application number
NO984106A
Other languages
English (en)
Norwegian (no)
Other versions
NO984106D0 (no
Inventor
Kelly Anne Brush
Marc Jerome Chapdelaine
William Jackson Frazee
Laura Enid Garcia-Davenport
Joseph James Lewis
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO984106D0 publication Critical patent/NO984106D0/no
Publication of NO984106L publication Critical patent/NO984106L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO984106A 1996-03-08 1998-09-07 Azolobenzazepin-derivater som neurologisk aktive midler NO984106L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1352896P 1996-03-08 1996-03-08
PCT/GB1997/000592 WO1997032883A1 (en) 1996-03-08 1997-03-04 Azolobenzazepine derivatives as neurologically active agents

Publications (2)

Publication Number Publication Date
NO984106D0 NO984106D0 (no) 1998-09-07
NO984106L true NO984106L (no) 1998-11-06

Family

ID=21760422

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984106A NO984106L (no) 1996-03-08 1998-09-07 Azolobenzazepin-derivater som neurologisk aktive midler

Country Status (13)

Country Link
US (2) US6124281A (Direct)
EP (1) EP0888350A1 (Direct)
JP (1) JP2000506160A (Direct)
KR (1) KR19990087585A (Direct)
CN (1) CN1084747C (Direct)
AU (1) AU723860B2 (Direct)
CA (1) CA2247453A1 (Direct)
IL (1) IL126095A0 (Direct)
NO (1) NO984106L (Direct)
NZ (1) NZ330973A (Direct)
TW (1) TW486480B (Direct)
WO (1) WO1997032883A1 (Direct)
ZA (1) ZA971964B (Direct)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW510902B (en) * 1997-09-29 2002-11-21 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
ES2312650T3 (es) 2001-12-26 2009-03-01 Meiji Seika Kaisha Ltd. Nuevo derivado de triazolobenzazepina triciclica cristalina.
EP1472252A1 (en) * 2002-02-07 2004-11-03 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN104193750B (zh) 2004-05-14 2018-04-27 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
CN104031049A (zh) 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311948D0 (en) * 1993-06-10 1993-07-28 Zeneca Ltd Substituted nitrogen heterocycles
JP3290664B2 (ja) * 1993-12-28 2002-06-10 明治製菓株式会社 ３環性ベンゾアゼピンおよびベンゾチアゼピン誘導体
CN1066148C (zh) * 1995-06-15 2001-05-23 明治制果株式会社 三环性苯并氮杂䓬化合物

Also Published As

Publication number Publication date
ZA971964B (en) 1997-09-08
IL126095A0 (en) 1999-05-09
CN1224424A (zh) 1999-07-28
US6313290B1 (en) 2001-11-06
US6124281A (en) 2000-09-26
CN1084747C (zh) 2002-05-15
NO984106D0 (no) 1998-09-07
WO1997032883A1 (en) 1997-09-12
TW486480B (en) 2002-05-11
JP2000506160A (ja) 2000-05-23
CA2247453A1 (en) 1997-09-12
NZ330973A (en) 2000-03-27
KR19990087585A (ko) 1999-12-27
AU2225397A (en) 1997-09-22
EP0888350A1 (en) 1999-01-07
AU723860B2 (en) 2000-09-07

Similar Documents

Publication Publication Date Title
NO984106L (no) Azolobenzazepin-derivater som neurologisk aktive midler
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
NO983749L (no) CCR-3 reseptor-antagonister
HUP0001062A2 (hu) NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények
BE1002212A5 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
NO162467C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo (1,5)-pyridiner og deres dihydro- og tetrahydroderivater.
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
NO994452L (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
DK165447C (da) 2-pyrimidinyl-1-piperazin-derivater, fremgangsmaader til deres fremstilling og laegemidler indeholdende dem
HUP9801340A1 (hu) Triciklusos pirazolszármazékok és az azokat tartalmazó gyógyszerkészítmények
DK0484573T3 (da) Physostigmin-beslægtede 4- og 6-carbamater, en fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
SE8405754D0 (sv) 7-karboximetoxi-furo-(3,4-c)-pyridinderivat, framstellning derav och terapeutiska kompositioner innehallande dem
TR200103349T2 (tr) Purin türevleri, hazırlama usulü ve bunları içeren ispençiyari bileşimleri.
DK158087D0 (da) Hidtil ukendte benzothiazinderivater og sammensaetning indeholdende samme
SI1216245T1 (en) Pharmaceutically active sulfonyl hydrazide derivatives
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
NO965444L (no) Triterpen-derivat samt medikamentell sammensetning omfattende dette
NO904801L (no) Fremgangsmaate for fremstilling av acat-inhibitorer.
MX9803730A (es) Nuevo proceso de preparacion de derivados de fenilimidazolidina.
FR2696466B1 (fr) Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
MA26721A1 (fr) Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application